Competitive intelligence

Who else is working on your target, and on what evidence

Atlas identifies the companies, universities, hospitals and research institutes active on your project's subject, from the trials, patents, grants and papers it already holds. Each organization gets a sourced profile; you decide who is a competitor, a partner or someone to watch.

What is competitive intelligence in biotech R&D?

Competitive intelligence in drug development maps the organizations working on the same target or indication: their molecules, trials, patents, funding and publications. Teams use it to position a program, anticipate readouts and spot potential partners. Built by hand, it means searching registries, patent offices and literature one organization at a time.

With Atlas

  • Identifies organizations from the evidence already in your project
  • Gives each one a factual reason for being listed, with its source
  • Assembles a profile: programs, trials, patents, grants, papers, timeline
  • Summarizes it briefly, from that evidence only, with a date

Step 1 of 3

Organizations come from your evidence, each with a reason

An organization is listed because the project’s evidence names it in a role: sponsor of a trial on the target, applicant on a relevant patent family, holder of a grant, documented affiliation of a paper. A name that only appears in a reference list is not enough.

In the KRAS G12C example, the phase 3 trials alone bring in Eli Lilly and Company, Amgen, Mirati Therapeutics Inc., Hoffmann-La Roche.

Lead sponsors in the KRAS G12C exampletrials, as registered
Mirati Therapeutics Inc.8
Hoffmann-La Roche4
M.D. Anderson Cancer Center4
Amgen2
Eli Lilly and Company2
Genentech, Inc.2

One evidence type only, trial sponsorship, from the 50 trials of the example project, read on 30 Oct 2026. Atlas adds patents, grants and papers.

Step 2 of 3

One profile per organization, built from sources

The profile brings together what is scattered across modules: the organization’s programs, trials, patents, grants and publications, on a timeline, with a development pipeline and an activity chart when the data allows.

Different roles stay distinct, and names are merged with care: a subsidiary, a parent company or a namesake is not folded into another organization on resemblance alone.

What an organization profile gathersfrom the project's evidence
Programs
The molecules and indications the evidence attributes to the organization
Trials
Trials it sponsors or collaborates on, with phase and status
Patents
Patent families where it is an applicant
Grants
Public grants it holds, from NIH RePORTER and CORDIS
Publications
Papers with a documented affiliation, funding or conflict-of-interest link
Timeline
Dated events across all of the above

Step 3 of 3

A short summary you can check, line by line

Atlas does not crawl company websites or pull in unsourced web content: everything in a profile comes from registries, patent offices, grant databases and the literature, and opens on the record it came from.

No threat score, no ranking of rivals: the judgment stays with you.

How the summary is writtenthree rules
  • Generated from the evidence in the profile, nothing else
  • Each statement opens on its source in the inspector
  • Dated, and refreshed when you ask for it

Map the organizations around your target

We set up a project on your disease and target with you and walk through the organizations Atlas identifies.

Request a demo

Example: lead sponsors as registered on ClinicalTrials.gov for the 50 trials of the Atlas project “KRAS G12C NSCLC Landscape”, read on 30 Oct 2026. Sponsor names are not normalized: an acquired company keeps the name under which it registered the trial.